Clinical trials
catalyst calendar across sponsors →Studies where CATX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 7 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, +2 more) · FINRA short interest 25.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsNCT05636618Number of participants with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT-α-NETNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: [203Pb]VMT-α-NET, [212Pb]VMT-α-NET | Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma | 300 | 2029-11-26 | in 1,195 d | 2026-05-14 |
| Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2028-01-31 | in 530 d | 2026-07-06 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaNCT05655312Number of subjects with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT01 as a monotherapy or in combination with nivolumab.Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: [203Pb]VMT01, [212Pb]VMT01, Nivolumab | Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III | 300 | 2027-12-31 | in 499 d | 2026-06-10 |
| Targeted Imaging of Melanoma for Alpha-Particle RadiotherapyNCT04904120Number of Participants with Study Imaging Agent-Associated Adverse Events (AE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.Randomized · Single-masked · Diagnostic | Phase 1 | Completed | Drug: [203Pb]VMT01, [68Ga]VMT02 | Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal | 7 | 2022-09-20actual | — | 2023-11-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19